With FDA staff opposed to Sarepta therapy, top official intervened; scientists look to bears for a possible way to treat blood clots

Inside the FDA office that oversees gene therapies, some staff believed Sarepta's gene therapy for Duchenne should be rejected.

April 13, 2023 Check out STAT+

Sponsored By

Kristoffer Tripplaar/Sipa via AP STAT+ | FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened Inside the FDA office that oversees gene therapies, some staff believed Sarepta's gene therapy for Duchenne should be rejected. By Adam Feuerstein and Jason Mast Abortion drug battle will head to Supreme Court after appeals court decision The judges said it could no longer be sent to patients through the mail and that it could only be used up to seven weeks into a pregnancy. By Andrew Joseph and Sarah Owermohle STAT+ | Pear Therapeutics dreamt of huge revenues and 'commercial scale.' It never came close Pear Therapeutics said it would grow from $4 million in 2021 to a whopping $125 million by the end of 2023. It didn't come close. By Mario Aguilar Courtesy Ole Frøbert Scientists, going on a bear hunt, find a potential way to treat deadly blood clots The finding raises hope that researchers can develop drugs against blood clots, which kill up to 100,00 Americans every year. By Jason Mast STAT+ | Google will let health care customers test its generative AI model, ramping up rivalry with GPT-4 Accelerating medicine's AI race, Google is releasing a version of its generative language model Med-Palm 2 to health care customers. By Casey Ross STAT+ | Federal group studying surprise ambulance bills will finally meet — four months late The committee in charge of stopping surprise billing from ambulances and health insurers will finally meet, four months late. By Bob Herman Jerome Delay/AP Promising new malaria vaccine for kids approved in Ghana Preliminary results have suggested the vaccine is far more effective than the only malaria vaccine now authorized for use by the WHO. By Sam Mednick — Associated Press Listen: How the legal battle over abortion could thwart research, plus: the FDA 'bully pulpit' and Moderna's future Ovid Therapeutics CEO Jeremy Levin joins us to discuss a judge's decision to overturn the FDA approval of the abortion pill mifepristone. By Damian Garde and Meg Tirrell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser